Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Otsuka Pharmaceutical Co Ltd
Otsuka Pharmaceutical Co Ltd_20131212

Otsuka Pharmaceutical Co Ltd patents


Recent patent applications related to Otsuka Pharmaceutical Co Ltd. Otsuka Pharmaceutical Co Ltd is listed as an Agent/Assignee. Note: Otsuka Pharmaceutical Co Ltd may have other listings under different names/spellings. We're not affiliated with Otsuka Pharmaceutical Co Ltd, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "O" | Otsuka Pharmaceutical Co Ltd-related inventors


 new patent  Pharmaceutical preparation comprising brexpiprazole and substituted beta-cyclodextrin

Provided is an aqueous pharmaceutical preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (compound (I)) or a salt thereof, which shows improved water solubility of compound (I) or a salt thereof achieved by addition of substituted β-cyclodextrin. The present invention provides a pharmaceutical preparation comprising compound (I) or a salt thereof, and substituted β-cyclodextrin.... Otsuka Pharmaceutical Co Ltd

 new patent  Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1 -yl)butoxy]-1h-quinolin-2-one or a salt thereof

and further comprising a coating layer, containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.... Otsuka Pharmaceutical Co Ltd

Method for quantitative measurement of gastric acidity using 13c carbonate salt

(3) determining the gastric acidity of the mammalian subject based on a difference between the reference 13CO2 behavior and the measured 13CO2 behavior obtained above.... Otsuka Pharmaceutical Co Ltd

Piperazine-substituted benzothiophenes for treatment of mental disorders

The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.... Otsuka Pharmaceutical Co Ltd

Quinolone compound

wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R2 is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.;... Otsuka Pharmaceutical Co Ltd

Controlled release sterile injectable aripiprazole formulaton and method

A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A... Otsuka Pharmaceutical Co Ltd

Systems, devices, and methods for ingestible event sensing and analysis

In some embodiments, a system includes an ingestible signal generator coupled to a medication and configured to generate a body-transmissible signal upon ingestion by a user. The system also includes a receiver, the receiver including a sensor configured to detect the body-transmissible signal, the receiver configured to generate and wirelessly... Otsuka Pharmaceutical Co Ltd

4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer

The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one... Otsuka Pharmaceutical Co Ltd

Method for evaluating efficacy of chemoradiotherapy against squamous cell carcinoma

(c) determining that an efficacy of a chemoradiotherapy against squamous cell carcinoma in the subject is high if the expression level in the subject is higher than the reference expression level as a result of the comparison in the step (b).... Otsuka Pharmaceutical Co Ltd

Oral solid preparation comprising aripiprazole and producing oral solid preparation comprising aripiprazole

[Means for Achieving the Object] The present invention relates to an oral solid preparation comprising, as an active ingredient, a finely milled crystal obtained by milling an aripiprazole hydrate crystal, and a pharmaceutically acceptable carrier, the finely milled crystal having a mean particle size of 15 μm or less; and... Otsuka Pharmaceutical Co Ltd

Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof

The present invention relates to a prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.... Otsuka Pharmaceutical Co Ltd

Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram,... Otsuka Pharmaceutical Co Ltd

Heterobicyclic compounds and their use for the treatment of tuberculosis

wherein each symbol is defined as described in the attached specification, or a salt thereof.... Otsuka Pharmaceutical Co Ltd

Drug for preventing and/or treating polycystic kidney disease

An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative,... Otsuka Pharmaceutical Co Ltd

Piperazine-substituted benzothiophenes for treatment of mental disorders

The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.... Otsuka Pharmaceutical Co Ltd

Method of treating bipolar i and ii disorders

wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.... Otsuka Pharmaceutical Co Ltd

Heterocyclic compounds for treating or preventing disorers caused by reduced neurotransmission of serotonin, norephnephrine or dopamine

the aromatic or heterocyclic group may have one or more arbitrary substituent(s).... Otsuka Pharmaceutical Co Ltd

Oxazole compound and pharmaceutical composition

wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(═O)— wherein Y1 is a group such... Otsuka Pharmaceutical Co Ltd

Agent for improving or maintaining qol

A QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent containing Lactobacillus ONRICb0240 (FERM BP-10065).... Otsuka Pharmaceutical Co Ltd

Therapeutic compounds and related methods of use

Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit.... Otsuka Pharmaceutical Co Ltd

Oral formulation

Provided are an oral formulation capable of improving easy administrability and showing good preservation stability, and a substrate for oral formulation. An oral formulation containing a medicament; sugar alcohol; one or more kinds of hydrophilic polysaccharides selected from the group consisting of acacia, pullulan and maltodextrin; a gelling agent; and... Otsuka Pharmaceutical Co Ltd

Drug for preventing and/or treating polycystic kidney disease

An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative,... Otsuka Pharmaceutical Co Ltd

Preventive or therapeutic agent for fibrosis

Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.... Otsuka Pharmaceutical Co Ltd

Energy malnutrition evaluation for liver disease test subject

A method for measuring energy malnutrition in a liver disease test subject, a method for determining whether a liver disease test subject is in an energy malnutrition state, a method for determining the necessity of nutrition therapy for a liver disease test subject having energy malnutrition, a composition usable in... Otsuka Pharmaceutical Co Ltd

Medical tablet, and manufacturing method and manufacturing medical tablet

An object is to provide a tablet manufacturing apparatus capable of supplying an IC chip to a desired position of pharmaceutical powder with a high accuracy and suppressing a positional displacement. The IC chip is supported by a positioning guide with a chip main body in a downward manner, and... Otsuka Pharmaceutical Co Ltd

Solution for oral administration

Provided is a solution suitable for oral administration of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (compound (I)) or a salt thereof. A solution for oral administration containing compound (I) or a salt thereof, and at least one compound selected from the group consisting of lactic acid, phosphoric acid, glycolic acid, malic acid, tartaric acid, citric... Otsuka Pharmaceutical Co Ltd

Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof

and further comprising a coating layer containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.... Otsuka Pharmaceutical Co Ltd

N,n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors

or a salt thereof, wherein R101 and R102 are each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine... Otsuka Pharmaceutical Co Ltd

Pharmaceutical preparation comprising brexpiprazole and substituted beta-cyclodextrin

Provided is an aqueous pharmaceutical preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (compound (I)) or a salt thereof, which shows improved water solubility of compound (I) or a salt thereof achieved by addition of substituted β-cyclodextrin. The present invention provides a pharmaceutical preparation comprising compound (I) or a salt thereof, and substituted β-cyclodextrin.... Otsuka Pharmaceutical Co Ltd

Oral solid preparation comprising aripiprazole and producing oral solid preparation comprising aripiprazole

[Means for Achieving the Object] The present invention relates to an oral solid preparation comprising, as an active ingredient, a finely milled powder obtained by milling a highly hygroscopic aripiprazole anhydrous crystal, and a pharmaceutically acceptable carrier, the finely milled powder having a mean particle size of 10 μm or... Otsuka Pharmaceutical Co Ltd

Novel lactobacillus paracasei strain

Lactobacillus paracasei having polyamine production promoting activity in an organism.... Otsuka Pharmaceutical Co Ltd

Method for measuring anti-wt1 antibody

Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method. The method for measuring an anti-WT1 antibody in a sample includes using a polypeptide having antigenicity to... Otsuka Pharmaceutical Co Ltd

Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative

A suspension and a cake composition are provided in which agglomeration of the active ingredient that is caused when silicone oil and/or silicone oil derivative is contained therein can be suppressed without a special treatment, such as sonication. The suspension contains, in a dispersion medium, an active ingredient of a... Otsuka Pharmaceutical Co Ltd

Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder

The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt... Otsuka Pharmaceutical Co Ltd

C1q-adiponectin complex and use thereof

The present invention provides a C1q-adiponectin complex comprising naturally occurring adiponectin and C1q.... Otsuka Pharmaceutical Co Ltd

03/16/17 / #20170071933

Piperazine-substituted benzothiophene derivatives as antipsychotic agents

Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol... Otsuka Pharmaceutical Co Ltd

03/09/17 / #20170066752

Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases. The present invention provides a dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or of a salt thereof, and a process for producing the same.... Otsuka Pharmaceutical Co Ltd

02/16/17 / #20170042887

Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders

A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole... Otsuka Pharmaceutical Co Ltd

02/09/17 / #20170035752

Methods for producing aripiprazole suspension and freeze-dried formulation

Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 ?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g.,... Otsuka Pharmaceutical Co Ltd

01/05/17 / #20170000786

Piperazine-substituted benzothiophenes for treatment of mental disorders

The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.... Otsuka Pharmaceutical Co Ltd








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Otsuka Pharmaceutical Co Ltd in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Otsuka Pharmaceutical Co Ltd with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###